Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The initial consideration for the transaction is US$ 12 million
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
For the full year FY25, net profit soared 12x to Rs 345 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
